Nautilus Biotechnology reported second-quarter 2026 results, recognizing $0.2 million in revenue and a net loss of $14.5 million for the quarter ended June 30, 2026. Operating expenses were $15.9 million for the quarter, and the company held $129.2 million in cash, cash equivalents and investments as of June 30, 2026. Nautilus also announced product roadmap updates and the expansion of its Iterative Mapping Early Access program ahead of the Voyager platform launch.

Financial Highlights

  • Total revenue: $0.2 million for Q2 2026 (grant and service revenue) and $0.19 million for the three months ended June 30, 2026 as presented.
  • Cost of service revenue: $0.015 million for the three months ended June 30, 2026.
  • Operating expenses: $15.9 million for Q2 2026 (research & development $9.613 million; selling, general & administrative $6.325 million).
  • Net loss: $14.5 million for Q2 2026 and $29.166 million for the six months ended June 30, 2026.
  • Cash, cash equivalents and investments: $129.2 million as of June 30, 2026 (total assets $163.576 million; total stockholders’ equity $131.112 million).

Business Highlights

  • Recognized first revenue in Q2 2026, including Michael J. Fox Foundation grant supporting alpha-synuclein proteoform assay development and service revenue from the Iterative Mapping Early Access Program.
  • Expanded commercial organization to three team members, including a VP of Global Sales, to drive engagement ahead of the Voyager platform commercial launch.
  • Realigned product roadmap to accelerate proteoform applications: Voyager platform pre-orders expected early 2027 with instrument shipments beginning mid-2027.
  • Proteoform portfolio advancement: Tau Proteoforms Assay available via Iterative Mapping Early Access (consumable kits GA mid-2027); AKT1 Proteoforms Assay targeted for Early Access in late 2026 and consumable kits GA mid-2027; additional oncology proteoform assays planned for mid- and late-2027.
  • Broadscale assay development: assay configuration changes did not meet 2027 GA target specifications; key improvement areas identified and development work initiated with a commercial timeline to be reported later.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.